The 3-weekly regimen of carboplatin and paclitaxel is the backbone of first line adjuvant
chemotherapy for advanced ovarian cancer. The landmark Japanese Gynaecologic …

Because most patients presenting with advanced ovarian cancer are not curable by surgery
alone, chemotherapy represents an essential component of treatment. The disease may be …

Background Platinum-resistant ovarian cancer is characterized by its poor prognosis and
limited treatment options. Anlotinib is a novel tyrosine kinase inhibitor targeting multiple …

Objectives: Synergism between gemcitabine and platinum is known clinically. Bevacizumab
in combination with single-agent chemotherapy has demonstrated significant clinical activity …

Objective: Bevacizumab (B) added to paclitaxel/carboplatin (PC) followed by maintenance B
improved progression-free survival (PFS) in 2 contemporaneous phase III trials (GOG-0218 …

There is little doubt that the survival of women with advanced ovarian cancer has improved
over the last two decades. 1 Platinum and paclitaxel are the two key drugs that have now …

Background Vandetanib is an oral tyrosine kinase inhibitor of VEGFR-2/3, EGFR and RET,
which has demonstrated clinical activity as a single agent and in combination with taxanes …

Introduction/Background First-line phase III trials in stage III/IV Epithelial Ovarian Cancer
(EOC) have shown improved survival both with addition of bevacizumab (BEV) to three …

Despite improvements in surgical and diagnostic techniques, the outcome for women with
advanced epithelial ovarian cancer remains poor. Recent developments in the …

Objectives: The purpose of this study was to assess the toxicity, progression-free survival,
and response rate of advanced stage ovarian carcinoma patients treated with a novel …